Abdominal wall metastases due to a squamous cell carcinoma of the lung: Case report and literature review

Ioniță, Corina Florica; Cojocaru, Ioana Iulia; Gomotîrceanu, Adriana; Suciu, Bogdan Andrei; Milutin, Doina; Butilcă, Alexandru Ilie; Molnar, Călin Dragoș; Halmaciu, Ioana

doi:10.2478/amma-2022-0010

References

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-24910.3322/caac.20006
Search in Google Scholar Back to article
2. Jacobsen J, Pirl WF, Billings JA, Lynch TJ. Early palliative care for patients with metastatic non-small-cell lung cancer, N Engl J Med., 2010;363(8):733-74210.1056/NEJMoa1000678
Search in Google Scholar Back to article
3. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship., Mayo Clin Proc., 2008;83(5):584-594. doi: 10.4065/83.5.584
Open DOI Search in Google Scholar Back to article
4. Simeone JC, Nordstrom BL, Patel K, Klein AB. Treatment patterns and overall survival in metastatic non-small-cell lung cancer in a real-world, US setting., Future Oncol 2019;15(30):3491-3502. doi: 10.2217/fon-2019-0348
Open DOI Search in Google Scholar Back to article
5. Bi N, Yang M, Zhang L, Chen X, Ji W, Ou G, Lin D, Wang L. Cyclooxygenase-2 genetic variants are associated with survival in unresectable locally advanced non-small cell lung cancer., Clin Cancer Res. 2010 Apr 15;16(8):2383-2390. doi: 10.1158/1078-0432.CCR-09-2793
Open DOI Search in Google Scholar Back to article
6. Riihimäki M, Hemminki A, Fallah M, Thomsen H, Sundquist K, Sundquist J, Hemminki K. Metastatic sites and survival in lung cancer., Lung Cancer 2014;86(1):78-84. doi: 10.1016/j.lungcan.2014.07.020
Open DOI Search in Google Scholar Back to article
7. Quint LE, Tummala S, Brisson LJ, Francis IR, Krupnick AS, Kazerooni EA, Iannettoni MD, Whyte RI, Orringer MB.Distribution of distant metastases from newly diagnosed non-small cell lung cancer., Ann Thorac Surg. 1996;62(1):246-250. doi: 10.1016/0003-4975(96)00220-2
Open DOI Search in Google Scholar Back to article
8. Socinski MA, Morris DE, Masters GA, Lilenbaum R. American College of Chest Physicians., Chemotherapeutic management of stage IV non-small cell lung cancer., Chest. 2003 Jan;123(1 Suppl):226S-243S. doi: 10.1378/chest.123.1_suppl.226s
Open DOI Search in Google Scholar Back to article
9. Kagohashi K, Satoh H, Ishikawa H, Ohtsuka M, Sekizawa K. Liver metastasis at the time of initial diagnosis of lung cancer., Med Oncol., 2003;20(1):25-28. doi: 10.1385/MO:20:1:25
Open DOI Search in Google Scholar Back to article
10. Sawyer TE, Bonner JA, Gould PM, Deschamps C, Lange CM, Li H. Patients with stage I non-small cell lung carcinoma at postoperative risk for local recurrence, distant metastasis, and death: implications related to the design of clinical trials., Int J Radiat Oncol Biol Phys., 1999;45(2):315-321. doi: 10.1016/s0360-3016(99)00189-3
Open DOI Search in Google Scholar Back to article
11. Vidarsdottir H, Tran L, Nodin B, Jirström K, Planck M, Mattsson JSM, Botling J, Micke P, Jönsson P, Brunnström H. Comparison of Three Different TTF-1 Clones in Resected Primary Lung Cancer and Epithelial Pulmonary Metastases., Am J Clin Pathol. 2018;150(6):533-544. doi: 10.1093/ajcp/aqy083
Open DOI Search in Google Scholar Back to article
12. Gremel G, Bergman J, Djureinovic D, Edqvist PH, Maindad V, Bharambe BM, Khan WAZA, Navani S, Elebro J, Jirström K, Hellberg D, Uhlén M, Micke P, Pontén F. A systematic analysis of commonly used antibodies in cancer diagnostics., Histopathology.2014;64(2):293-305. doi: 10.1111/his.1225524330150
Open DOI Search in Google Scholar Back to article
13. Turner BM, Cagle PT, Sainz IM, Fukuoka J, Shen SS, Jagirdar J. Napsin A, a new marker for lung adenocarcinoma, is complementary and more sensitive and specific than thyroid transcription factor 1 in the differential diagnosis of primary pulmonary carcinoma: evaluation of 1674 cases by tissue microarray., Arch Pathol Lab Med. 2012;136(2):163-171. doi: 10.5858/arpa.2011-0320-OA22288963
Open DOI Search in Google Scholar Back to article
14. Xu B, Abourbih S, Sircar K, Kassouf W, Aprokian A, Tanguay S, Brimo F., Diagnostic and prognostic role of immunohistochemical expression of napsin-A aspartic peptidase in clear cell and papillary renal cell carcinoma: a study including 233 primary and metastatic cases., Appl Immunohistochem Mol Morphol. 2014;22(3):206-212. doi: 10.1097/PAI.0b013e31828ef24e23702650
Open DOI Search in Google Scholar Back to article
15. Kaufmann O, Fietze E, Mengs J, Dietel M. Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas., Am J Clin Pathol. 2001;116(6):823-830. doi: 10.1309/21TW-2NDG-JRK4-PFJX11392877
Open DOI Search in Google Scholar Back to article
16. Hoang LL, Tacha D, Bremer RE, Haas TS, Cheng L. Uroplakin II (UPII), GATA3, and p40 are Highly Sensitive Markers for the Differential Diagnosis of Invasive Urothelial Carcinoma., Appl Immunohistochem Mol Morphol. 2015;23(10):711-716. doi: 10.1097/PAI.000000000000014325611245
Open DOI Search in Google Scholar Back to article
17. Chu P, Wu E, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases., Mod Pathol. 2000;13(9):962-72. doi: 10.1038/modpathol.388017511007036
Open DOI Search in Google Scholar Back to article
18. Smith RA., Manassaram-Baptiste D., Brooks D., Doroshenk M., Fedewa S., Saslow D., Brawley OW, Wender R. Cancer screening in the United States, 2015: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin 2015;65(1):30-54. doi: 10.3322/caac.2126125581023
Open DOI Search in Google Scholar Back to article
19. Wang X, Adjei AA. Lung cancer and metastasis: new opportunities and challenges., Cancer Metastasis Rev 2015;34(2):169-171. doi: 10.1007/s10555-015-9562-425956388
Open DOI Search in Google Scholar Back to article
20. Wao H, Mashkar R, Kumar A, Miladinovic B, Djulbegovic B. Survival of patients with non-small cell lung cancer without treatment: a systematic review and meta-analysis., Syst Rev 2013;2:10. doi: 10.1186/2046-4053-2-10.357976223379753
Open DOI Search in Google Scholar Back to article
21. Lu J, Zhong H, Chu T, Zhang X, Li R, Sun J, Zhong R, Yang Y, Alam MS, Lou Y, Xu J, Zhang Y, Wu J, Li X, Zhao X, Li K, Lu L, Han B. Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy., Eur Respir J. 2019;53(3):1801562. doi: 10.1183/13993003.01562-201830578392
Open DOI Search in Google Scholar Back to article
22. Ettinger DS, Wood DE, Aisner DL, et al. Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology., J Natl Compr Canc Netw 2017 Apr;15(4):504-53510.6004/jnccn.2017.005028404761
Search in Google Scholar Back to article
23. Hanna N, Johnson D, Temin S, Baker S Jr, Brahmer J, Ellis PM, Giaccone G, Hesketh PJ, Jaiyesimi I, Leighl NB, Riely GJ, Schiller JH, Schneider BJ, Smith TJ, Tashbar J, Biermann WA, Masters G. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update, J Clin Oncol. 2017 Oct 20;35(30):3484-3515. doi: 10.1200/JCO.2017.74.606528806116
Open DOI Search in Google Scholar Back to article
24. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021, CA Cancer J Clin. 2021;71(1):7-33. doi: 10.3322/caac.2165433433946
Open DOI Search in Google Scholar Back to article
25. Xiang M, Yang X, Ren S, Du H, Geng L, Yuan L, Wen Y, Lin B, Li J, Zhang Y, Feng G, Du X. Anlotinib Combined with S-1 in Third- or Later-Line Stage IV Non-Small Cell Lung Cancer Treatment: A Phase II Clinical Trial., Oncologist. 2021;26(12):e2130-e2135. doi: 10.1002/onco.13950864904934423518
Open DOI Search in Google Scholar Back to article
26. Postow MA, Callahan MK, Wolchok JD. Immune Checkpoint Blockade in Cancer Therapy., J Clin Oncol. 2015;33(17):1974-82. doi: 10.1200/JCO.2014.59.4358498057325605845
Open DOI Search in Google Scholar Back to article
27. Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P, Belderbos J, Clamon G, Ulutin HC, Paulus R, Yamanaka T, Bozonnat MC, Uitterhoeve A, Wang X, Stewart L, Arriagada R, Burdett S, Pignon JP. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer., J Clin Oncol. 2010;28(13):2181-2190. doi: 10.1200/JCO.2009.26.254320351327
Open DOI Search in Google Scholar Back to article
28. Vinod SK, Hau E. Radiotherapy treatment for lung cancer: Current status and future directions., Respirology. 2020;25 Suppl 2:61-71. doi: 10.1111/resp.1387032516852
Open DOI Search in Google Scholar Back to article
29. Delaney GP, Barton MB. Evidence-based estimates of the demand for radiotherapy., Clin Oncol (R Coll Radiol). 2015;27(2):70-6. doi: 10.1016/j.clon.2014.10.00525455408
Open DOI Search in Google Scholar Back to article
30. Brown S, Banfill K, Aznar MC, Whitehurst P, Faivre Finn C. The evolving role of radiotherapy in non-small cell lung cancer., Br J Radiol. 2019;92(1104):20190524. doi: 10.1259/bjr.20190524691335931535580
Open DOI Search in Google Scholar Back to article
31. Ashworth A, Rodrigues G, Boldt G, Palma D. Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature., Lung Cancer. 2013;82(2):197-203. doi: 10.1016/j.lungcan.2013.07.02624051084
Open DOI Search in Google Scholar Back to article

Abdominal wall metastases due to a squamous cell carcinoma of the lung: Case report and literature review

References

Paradigm

My account